CK19-20X-1WFA21-19-1 Thyroid Carcinoma

IHC of Cytokeratin 19 on an FFPE Thyroid Carcinoma Tissue

Specification Sheets
Safety Data Sheet

SDS

Intended Use For In Vitro Diagnostic Use
Summary and Explanation Cytokeratin 19 is a Type I cytokeratin. Unlike its related family members, this smallest-known acidic cytokeratin is not paired with a basic cytokeratin in epithelial cells. It is specifically found in the periderm, the transientlysuperficial layer that envelopes the developing epidermis.Anti-Cytokeratin 19 reacts with a wide variety of epithelium and epithelial malignancies including Adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver and breast. Perhaps the most useful application is the identification of Thyroid Carcinoma of the papillary type, although Follicular Carcinoma is also labeled by
this antibody approximately 50-60% of the time. Cytokeratin 19 is not expressed in hepatocytes; therefore, this antibody is useful in the identification of liver metastasis. The degree of Cytokeratin 19 positivity in Breast Cancer distinguishes malignant from benign tumors. Cytokeratin 19 is often coexpressed with Cytokeratin 7.
Antibody Type Mouse Monoclonal Clone BSB-34
Isotype IgG1/K Reactivity Paraffin, Frozen
Localization Cytoplasmic Control Colon, Bladder Thyroid Carcinoma, Colon Carcinoma
Presentation Cytokeratin 19 antibody is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
Availability
Catalog No. Antibody Type Dilution Volume/QTY
BSB 2733 Prediluted Ready-To-Use 3.0 ml
BSB 2734 Prediluted Ready-To-Use 7.0 ml
BSB 2735 Prediluted Ready-To-Use 15.0 ml
BSB 2736 Concentrated 1:100-1:500 0.1 ml
BSB 2737 Concentrated 1:100-1:500 0.5 ml
BSB 2738 Concentrated 1:100-1:500 1.0 ml
BSB 2739 Control Slides 5
Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.
Related Products